Algernon Pharmaceuticals Inc.

Equities

AGN

CA01559R4008

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 15:09:26 08/07/2024 BST			5-day change	1st Jan Change
0.125 ^CAD	0.00%		0.00%	+92.31%

04-30	Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI
04-10	Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding	CI

Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019

January 28, 2020 at 08:45 pm

Algernon Pharmaceuticals Inc. announced earnings results for the first quarter ended November 30, 2019. For the first quarter, the company announced net loss was CAD 166,337 compared to CAD 493,776 a year ago. Basic eps - continuing operations was CAD 0 compared to basic loss per share from continuing operations of CAD 0.01 a year ago.

Latest news about Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	04-30	CI
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding	04-09	CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.017 million in funding	04-02	CI
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset	04-01	CI
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company	03-27	MT
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc.	03-26	CI
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	01-31	MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	01-25	CI
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	01-24	CI
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	01-11	MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	12-29	CI
Algernon Pharmaceuticals Increased Private Placement	12-27	MT
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.28 million in funding	12-26	CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding	12-11	CI
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast	11-30	MT
Algernon Pharmaceuticals Brief: Says Received Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD	11-30	MT
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD	11-30	CI
Algernon Pharma in LOI For Acquisition of its Chronic Cough Research Program For US$2 Million and 20% Equity Stake	11-22	MT
Algernon Pharmaceuticals Brief: Announcing LOI for Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for US$2 Million and a 20% Equity Position	11-22	MT
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH	06/09/23	MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	28/07/23	CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.205 million in funding	13/07/23	CI
Algernon Pharmaceuticals Engages Maxim Group to Provide Financial Advisory and Investment Banking Services, and to Assist in Identifying and Evaluating Potential M&A and Strategic Opportunities	27/06/23	CI
Algernon Pharmaceuticals Engage Maxim Group to Explore Spin-Off of Ifenprodil Phase 2 Chronic Cough Drug Development Program	27/06/23	MT
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference	06/06/23	MT

Chart Algernon Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Companyâs lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

Sector

Biotechnology & Medical Research

Calendar

11/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALGERNON PHARMACEUTICALS INC.	+92.31%	2.01M
VERTEX PHARMACEUTICALS INCORPORATED	+18.34%	122B
REGENERON PHARMACEUTICALS, INC.	+19.71%	112B
BIONTECH SE	-23.89%	19.33B
GENMAB A/S	-18.45%	16.17B
BEIGENE, LTD.	-18.59%	15.6B
WUXI APPTEC CO., LTD.	-49.33%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.73%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+7.05%	14B
INSMED INCORPORATED	+126.75%	11.29B

Bio Therapeutic Drugs